GlassScriptPhysician profile
Kevin R Baxter
NPI 1609161686
$6,650.52
in general payments reported to CMS, 2019-2025
19 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,657 · 2020: $2,679 · 2021: $478 · 2022: $512 · 2023: $474 · 2024: $480 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $3,299.34 | 2019-2024 | |
| Allergan, INC. | $847.19 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $408.90 | 2021-2025 | Acthar |
| Alcon Vision LLC | $361.79 | 2019-2024 | Clareon |
| Abbvie INC. | $274.77 | 2022-2025 | Durysta |
| Sight Sciences, INC. | $254.91 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $193.67 | 2024-2025 | Istent Infinite, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Vantage Technology LLC | $146.38 | 2022-2023 | |
| Horizon Therapeutics Plc | $143.15 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $125.00 | 2023 | Infuse |
| Sun Pharmaceutical Industries INC. | $125.00 | 2020 | |
| Rxsight INC | $124.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $97.63 | 2020-2023 | |
| Coopervision INC. | $97.20 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $58.10 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $27.22 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $23.19 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Alimera Sciences, INC. | $22.64 | 2024 | Yutiq, Iluvien |
| Dompe US, INC. | $20.05 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.